Hospital Universitari Vall d'Hebron Research Institute
With
Hospital General Universitario Gregorio Marañon
Hospital Vall d'Hebron
Puerta de Hierro University Hospital
Hospital Clinic of Barcelona
Hospital Universitario Central de Asturias
Complejo Hospitalario de Toledo
Germans Trias i Pujol Hospital
Hospital Universitario Marqués de Valdecilla
Hospital Miguel Servet
Parc Taulí Hospital Universitari
Hospital de la Santa creu i Sant Pau - Barcelona
Hospital Universitari de Bellvitge
Hospital del Mar
University Hospital of Girona Dr. Josep Trueta
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients of both sexes with diagnosed compensated advanced chronic liver disease (cACLD) determined by hepatic stiffness on transient elastography \>15 kPa.
Age between 18 and 80 years, inclusive.
Absence of prior or current decompensation.
For women of childbearing age, a possible pregnancy will be ruled out by a pregnancy test prior to the start of the study. Following the test, the woman must use an effective contraceptive method during sexual intercourse (see Appendix I) in the days leading up to the start of treatment, and continue to use it throughout the treatment period, as well as for several days after its completion.
Signing of informed consent.
You may not be if
History or current presence of hepatocellular carcinoma.
Concomitant systemic disease with a short-term poor prognosis.
Pregnancy, breastfeeding, or refusal to use contraceptive measures during participation in the study.
Patients with compensated advanced chronic liver disease (cACLD) due to hepatitis B virus (HBV) under antiviral treatment, and those with cACLD due to hepatitis C virus (HCV) cured with antiviral treatment.
Clareo Health | Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
